Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA To Implement Recommendations From 510(k) Task Force Within Months

This article was originally published in The Gray Sheet

Executive Summary

FDA plans to implement recommendations from an internal 510(k) task force within months, Office of Device Evaluation Director Donna Bea Tillman said in a Sept. 25 memo to staff

You may also be interested in...



Shuren's CDRH Sets Ambitious 2010 Agenda: 510(k), PMA Changes Planned

CDRH launched an ambitious 2010 agenda Jan. 20 that includes changes to the 510(k) and PMA pre-market programs by this fall, harmonized international inspection activities by 2011 and unique device identifiers by 2013

Shuren's CDRH Sets Ambitious 2010 Agenda: 510(k), PMA Changes Planned

CDRH launched an ambitious 2010 agenda Jan. 20 that includes changes to the 510(k) and PMA pre-market programs by this fall, harmonized international inspection activities by 2011 and unique device identifiers by 2013

Tighter FDA Review Squeezing Device VCs

For over three decades, medical device investors have accepted the Food and Drug Administration's crucial role as traffic cop for their start-ups. Yes, the agency could be tough, but a green light opened a lucrative road for device companies. But venture capitalists are increasingly worried that tighter controls on regulation could endanger innovation.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT027993

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel